Ribupatide
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 675
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HRS9531 Tablet Group | n/r | n/r | n/r | n/r |
| HRS9531 Tablet Placebo Group | n/r | n/r | n/r | n/r |
Not shown
- HRS9531 Tablet Group: endpoint not reported
- HRS9531 Tablet Placebo Group: endpoint not reported